Floatz logo

Licogliflozin

Polycystic Ovary Syndrome

Novartis PharmaceuticalsSmall moleculePhase 2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
73/ 100

Competitive context

66 Active assets in the Polycystic Ovary Syndrome cohort.

Asset / SponsorPhaseRating
Semaglutide
Methodist Health System
Phase 4BBB
Hcg
Eman Basuni Ebrahim Mowad
Phase 4BBB
Liraglutide
Peking University Third Hospital
Phase 4BBB
FOLLITROPIN BETA
Universitair Ziekenhuis Brussel
Phase 4BBB
Drospirenone
Ege University
Phase 4BBB

View all 50 →

Same molecule, other indications

Licogliflozin is also rated in:

metabolic dysfunction-associated steatohepatitisDormant
B
Indicative ·
57 / 100
View asset →
obesity disorderDormant
CCC
Indicative ·
54 / 100
View asset →
Diabetes Mellitus and Heart FailureDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →